Burke Thomas Barrett Sells 50,000 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) CEO Burke Thomas Barrett sold 50,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now directly owns 63,172 shares in the company, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Pulse Biosciences Stock Performance

PLSE stock traded up $0.19 during trading on Friday, hitting $17.98. The company had a trading volume of 166,773 shares, compared to its average volume of 200,640. Pulse Biosciences, Inc. has a one year low of $6.59 and a one year high of $22.69. The business has a 50-day moving average of $17.90 and a 200-day moving average of $16.57.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the prior year, the business posted ($0.19) EPS.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a report on Thursday, December 12th.

Institutional Trading of Pulse Biosciences

A number of large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its position in shares of Pulse Biosciences by 23.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after purchasing an additional 9,639 shares in the last quarter. Rhumbline Advisers grew its position in shares of Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after buying an additional 1,608 shares during the period. Quest Partners LLC bought a new stake in shares of Pulse Biosciences in the 2nd quarter valued at $91,000. Creative Planning lifted its position in shares of Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after purchasing an additional 97,565 shares in the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.